{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:17:53Z","timestamp":1771010273751,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10157-013-0928-z","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T08:21:42Z","timestamp":1389255702000},"page":"282-285","source":"Crossref","is-referenced-by-count":12,"title":["Do statins play a role in renoprotection?"],"prefix":"10.1007","volume":"18","author":[{"given":"Masato","family":"Kasahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashige","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Yasuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mukoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"928_CR1","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","volume":"14","author":"ES Schaeffner","year":"2003","unstructured":"Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084\u201391.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"928_CR2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.HYP.26.4.670","volume":"26","author":"M M\u00e4ntt\u00e4ri","year":"1995","unstructured":"M\u00e4ntt\u00e4ri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26(4):670\u20135.","journal-title":"Hypertension"},{"key":"928_CR3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinte.158.9.998","volume":"158","author":"M Ravid","year":"1998","unstructured":"Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998\u20131004.","journal-title":"Arch Intern Med"},{"key":"928_CR4","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00125-012-2578-1","volume":"55","author":"T Kuwabara","year":"2012","unstructured":"Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Ogawa Y, Imamaki H, Kawanishi T, Ishii A, Koga K, Mori PK, Kato Y, Sugawara A, Nakao K. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia. 2012;55:2256\u201366.","journal-title":"Diabetologia"},{"key":"928_CR5","doi-asserted-by":"crossref","unstructured":"Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131\u20139.","DOI":"10.2215\/CJN.04371206"},{"key":"928_CR6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ndt\/gfl538","volume":"22","author":"VG Athyros","year":"2007","unstructured":"Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007;22:118\u201327.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"928_CR7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000046648","volume":"21","author":"T Nakamura","year":"2001","unstructured":"Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol. 2001;21(6):449\u201354.","journal-title":"Am J Nephrol"},{"issue":"5","key":"928_CR8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/17.5.798","volume":"17","author":"T Nakamura","year":"2002","unstructured":"Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002;17(5):798\u2013802.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"928_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10157-012-0676-5","volume":"17","author":"K Ueshima","year":"2013","unstructured":"Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, Yasuno S, Fujimoto A, Tanaka S, Kimura G, Nakao K. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2013;17(2):211\u20137.","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-013-0928-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-013-0928-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-013-0928-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T03:33:41Z","timestamp":1647920021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-013-0928-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s10157-013-0928-z","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]}}}